Lucas Montarce's most recent trade in Lilly(Eli) & Co was a trade of 2,895 Common Stock done at an average price of $869.2 . Disclosure was reported to the exchange on Feb. 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | Lucas Montarce | EVP & CFO | Grant, award, or other acquisition of securities at price $ 869.16 per share. | 10 Feb 2025 | 2,895 | 13,969 (0%) | 0% | 869.2 | 2,516,217 | Common Stock |
| Eli Lilly | Lucas Montarce | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 1,074 | 11,541 (0%) | 0% | 0 | Common Stock | |
| Eli Lilly | Lucas Montarce | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 1,074 | 0 | - | - | Restricted Stock Unit | |
| Eli Lilly | Lucas Montarce | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 819.27 per share. | 01 Nov 2024 | 467 | 11,073 (0%) | 0% | 819.3 | 382,601 | Common Stock |